Inova Health Care Services

ALEXANDRIA, Va., May 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Tina J. Falika King is acknowledged as a Pinnacle Life Member for her contributions to the field of Urology. Continue Reading Tina J, Falika King Dr. King's professional journey began in 2009 when she graduated from The Ohio State University College of Medicine and Public Health with a Master's degree in Public Health with a focus on Clinical Investigation and a Medical degree. She completed her general OB-GYN training at WellSpan York Hospital and further specialized in high-risk obstetrics training with the Perinatal Associates of Northern Virginia at Inova Fairfax Hospital. She later joined Inova Health System and has experience in private practice in Alexandria, Virginia. Known as a compassionate obstetrician-gynecologist with a focus on women's health, Dr. King has served at Inova Health System for 13 years, is affiliated with Inova Fairfax Hospital, and continues to have privileges at Inova Alexandria Hospital. Her special interests include high-risk pregnancies, uterine fibroids, fertility and eliminating healthcare disparities for women of color. The doctor is also a big proponent of patient education, intent to have patients be able to advocate for themselves and make informed decisions about their healthcare. In regards to her success in the field, Dr. King practices her philosophy of putting the patient first, emphasizing a patient-centered approach to healthcare by . The doctor is an avid reader of many professional journals, but her favorite publication is the "green journal," which refers to a medical journal related to obstetrics and gynecology. A revered author herself, Dr. King has worked with numerous experts in the field publishing works such as Impact of prenatal diagnosis of fetus-in-fetu in the Journal of Neonatal-Perinatal Medicine in 2017. The doctor serves in numerous professional capacities including Vice-Chair of Obstetrics at Inova Fairfax Hospital from 2021-2023 and notes that her success was directly impacted by her mentors who include the late Dr. Brenda Armstrong of Duke University; and Dr. Alfred Khoury of Perinatal Associates of Northern Virginia, Inova Fairfax Hospital. Dr. King's future projections include continuing to care for her patients and focusing on patient education and resident education in obstetrics and gynecology. Aside from her professional pursuits, Dr. King enjoys spending time with her family as a hobby and likes to travel to any destination offering a warm, sandy beach and good massage. She expresses gratitude to her husband, Aaron, and her children, Sterling and Aaryn, for their love and support. She also mentions her mother, Rebecca Falika, her mother-in-law, Dr. Rosalyn C. King, and her sister, Gwendolyn Burrell. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis BASEL, Switzerland--(BUSINESS WIRE)-- Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the U.S. Food and Drug Administration (FDA) has granted lixudebart (ALE.F02) Orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Dr. Luigi Manenti, Chief Medical Officer of Alentis said, “The Orphan Drug designation for lixudebart underscores the urgent medical need for an effective IPF treatment. We have completed IND-enabling studies for our IPF program, and we strongly believe that targeting CLDN1 in fibrotic lungs with our highly specific antibody has the potential to reverse the course of the disease.” “IPF patients do not have transformative treatment options and often experience tolerability challenges with the current standard of care drugs. Alentis is doing important work on developing lixudebart as a treatment targeting the root causes of disease,” added Prof. Steven Nathan, Medical Director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. “This molecule has shown a very favorable safety pro Phase 1, and I would be thrilled to see lixudebart tested in IPF patients in the future.” The FDA provides orphan status to drugs or biologics to prevent, diagnose or treat a rare disease or condition. Orphan Drug designation qualifies sponsors for certain incentives, including tax credits for qualified clinical trials, user-fee exemptions and a potential seven years of market exclusivity after approval. About lixudebart (ALE.F02) Lixudebart is a first-in-class monoclonal antibody developed for liver, lung and kidney fibrosis. The investigational antibody is designed to reverse organ fibrosis by specifically targeting a unique CLDN1 epitope exposed in fibrotic tissue. In Phase 1 single- and multiple-ascending dose studies in healthy volunteers lixudebart was observed to be well tolerated, with no serious safety concerns. Lixudebart is currently tested in clinical trials for advanced liver fibrosis (NCT05939947) and ANCA-associated vasculitis (NCT06047171). About IPF Idiopathic pulmonary fibrosis, or IPF, is a rare and serious chronic disease affecting tissue surrounding the air sacs or alveoli in the lungs, resulting in the thickening of lung tissue. Over time, this thickening causes permanent scarring of the lungs, called fibrosis, which makes breathing increasingly difficult. There is currently no cure for this condition with treatments only slowing the progression of IPF. About Alentis Therapeutics Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 antibodies and ADCs to modify and reverse the course of disease. Alentis was founded based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered at the pharma-biotech hub in Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit

Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary Fibrosis Avalyn to be featured in ATS Mini Theater Program and Respiratory Innovation Summit CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced multiple presentations at the 2024 American Thoracic Society (ATS) International Conference being held May 17-22, 2024 in San Diego, CA. Avalyn will also be featured in the ATS Industry Theater program, where the Company will share information about its Phase 2b trial evaluating AP01, a novel formulation of inhaled pirfenidone, for the treatment of progressive pulmonary fibrosis. Avalyn’s presentations at ATS will include long-term efficacy and tolerability data from the ongoing open-label extension portion of its ATLAS trial evaluating AP01 in patients with pulmonary fibrosis. Members of Avalyn leadership will also provide a poster presentation and moderate a panel during the Respiratory Innovation Summit, an associated meeting that unites pharma business development, venture capital, government, academia, and clinical medicine to advance respiratory discovery. “We are thrilled to have a lineup of presentations at ATS and are particularly excited to share the long-term efficacy and safety data on our flagship candidate, AP01, which bolsters our confidence in our planned Phase 2b trial in progressive pulmonary fibrosis,” said Lyn Baranowski, CEO of Avalyn Pharma. “These data, alongside our other presentations, underscore the transformative potential we aim to have by offering safe and effective inhaled therapies for patients with this life-threatening disease. Our showcase at ATS is a testament to the remarkable dedication and efforts of the Avalyn team plus the physicians and medical teams with whom we are working to address the critical needs in treating pulmonary fibrosis.” Avalyn’s abstracts for the conference are available on the ATS’s 2024 online program and the Company’s event schedule is outlined as follows: ATS 2024 Respiratory Innovation Summit Poster Presentation: Avalyn Pharma - Developing Targeted Inhaled Therapies for Patients with Rare Respiratory DiseasesPresenter: Allison Trucillo, M.D., Vice President, Medical Affairs at Avalyn PharmaTime: Poster available for viewing beginning May 17, 2024, at 5:00 p.m. PTLocation: Manchester Grand Hyatt San Diego Panel: Revisiting the Pulmonary Functions TestModerator: Craig S. Conoscenti, M.D., FCCP, ATSF, Senior Vice President, Clinical Development at Avalyn PharmaTime: May 18, 2024, at 3:45 p.m. PTLocation: Manchester Grand Hyatt San Diego ATS 2024 Poster Presentations Avalyn will deliver three poster presentations on May 20, 2024, from 11:30 a.m. – 1:15 p.m. PT at the San Diego Convention Center, Area K, Hall H: Title: Safety and Efficacy of Inhaled Pirfenidone (AP01) in the ATLAS Open-label Extension StudyThematic Poster Session: B48, Poster #: 1242 Title: Inhaled Pirfenidone Reduces the Risk of Disease Progression: A Post-hoc Analysis of the ATLAS StudyThematic Poster Session: B48, Poster #: 1244 Title: Differences in E-lung Biomarker Scores Between Treatment Groups in Post-hoc Analysis of the ATLAS Inhaled Pirfenidone Solution (AP01) for IPF Clinical TrialThematic Poster Session: B48, Poster #: 1251 ATS 2024 Industry Theater Conference Event Title: Breathing Innovation: Inhaled Pirfenidone for the Treatment of Progressive Pulmonary FibrosisPresenters: Howard Lazarus, M.D., Chief Medical Officer at Avalyn Pharma; Steven Nathan, M.D., FCCP, Medical Director, Advanced Lung Disease and Lung Transplant Program at Inova Fairfax HospitalSession: Interstitial Lung Disease Time: May 20, 2024, at 1:00 p.m. PTLocation: San Diego Convention Center, Innovation Theater 2 ATS 2024 Scientific Symposium Title: Designing a Clinical Trial with Diversity and Inclusion in MindPresenter: Craig S. Conoscenti, M.D., FCCP, ATSF, Senior Vice President, Clinical Development at Avalyn PharmaSession: SPS6 - Population Diversity in Clinical TrialsTime: May 20, 2024, at 2:32 p.m. PTLocation: Marriott Marquis San Diego Marina, Marina Ballroom E, Level 3 About Avalyn PharmaAvalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com. Investor Contact:Monique AllaireTHRUST Strategic Communicationsmonique@thrustsc.com